Apelin-36 is primarily studied for its role in cardiovascular regulation, where it acts as a potent vasodilator, helping to lower blood pressure and improve blood flow. It is also being explored for its potential in treating heart failure, as it enhances cardiac contractility and reduces vascular resistance. In metabolic research, Apelin-36 shows promise in regulating glucose metabolism and insulin sensitivity, making it a potential target for diabetes management. Additionally, it is investigated for its neuroprotective effects, particularly in conditions like stroke and neurodegenerative diseases, due to its ability to modulate inflammation and oxidative stress. Research is ongoing to harness its therapeutic potential in these areas.